Pivotal Trial (D02) of Vagus Nerve Stimulation (VNS) for Treatment-Resistant Depression (TRD)
NCT ID: NCT00533832
Last Updated: 2007-09-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
266 participants
INTERVENTIONAL
2000-07-31
2005-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Patients implanted with the vagus nerve stimulation (VNS) device and receiving VNS Intervention: vagus nerve stimulation (VNS)
vagus nerve stimulation (VNS)
intermittent vagus nerve stimulation
Placebo group were implanted, but did not receive vagus nerve stimulation during the acute phase.
2
Implanted with vagus nerve stimulation (VNS) device, but not receiving VNS
vagus nerve stimulation (VNS)
intermittent vagus nerve stimulation
Placebo group were implanted, but did not receive vagus nerve stimulation during the acute phase.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
vagus nerve stimulation (VNS)
intermittent vagus nerve stimulation
Placebo group were implanted, but did not receive vagus nerve stimulation during the acute phase.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. chronic (\>=2 years)or recurrent (\>-=4) lifetime MDEs
3. resistant to \>=2 treatments from different categories
4. completed \>=6 weeks of psychotherapy
5. score \>=20 on 24-item Hamilton Rating Scale of Depression
6. IQ \>=70
7. stable on current antidepressant medication (no more than 5 antidepressant meds) or taking no antidepressant meds for \>=4 weeks before Visit B1
8. stable on atypical antipsychotic and anticonvulsant medications as for item #7
9. age \>=18 amd \<=80 years
10. male or nonpregnant female adequately protected from conception.
11. able to comply with testing and follow-up visits
12. voluntarily signed informed consent
13. patients with bipolar disorder demonstrated a resistance to lithium treatment or has a medical contraindication to treatment with lithium or is known to be intolerant to lithium (not applicable to patients with MDD)
Exclusion Criteria
2. history of schizophrenia, schizoaffective disorder, or delusional disorders
3. rapid cycling bopolar disorder
4. secondary diagnosis of, or signs of, delirium, dementia, amnestic, or other cognitive disorders
5. failed 7 or more antidepressant treatments
6. a. suicide attempt requiring medical attention within previous 12 months b. \>=2 suicide attempts in the past 12 months c. cannot guarantee that will not implement suicide d. likely to attempt suicide within next 6 mon in investigator's opinion
7. alcohol or substance dependence within previous 12 months or abuse within previous 6 mon other than nicotine dependence or abuse
8. history of myocardial infarction or cardiac arrest
9. other progressive neurological disease, significant central nervous system disease or injury, or cervical fracture that makes implantation difficult
10. received general anesthesia with 390 days before enrollment.
11. taken an investigational drug within a clearance duration of 5 x the half-life of the investigational drug or within \<=4weeks before Visit B1, whichever time is greater
12. enrolled in another investigational study
13. using another investigational device
14. significant cardiac or pulmonary condition currently under treatment resulting in an ASA score \>=III
15. history of, or evidence of, significant brain malformation or significant head injury or clinically apparent cerebral vascular events, or prior brain surgery such as cingulatomy
16. unilateral or bilateral cervical vagotomy
17. demand cardiac pacemaker, implantable defibrillator, or other implantable stimulator
18. likely to require a whole body MRI after NCP implantation
19. currently receiving or likely to receive short-wave diathermy, microwave diathermy, or therapeutic ultrasound diathermy after implantation
20. plans to relocate or move to a location distant from the study site within one year of enrollment
21. previously enrolled in this or any other NCP System study -
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cyberonics, Inc.
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Investigator
Role: STUDY_DIRECTOR
Cyberonics, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
George MS, Rush AJ, Marangell LB, Sackeim HA, Brannan SK, Davis SM, Howland R, Kling MA, Moreno F, Rittberg B, Dunner D, Schwartz T, Carpenter L, Burke M, Ninan P, Goodnick P. A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol Psychiatry. 2005 Sep 1;58(5):364-73. doi: 10.1016/j.biopsych.2005.07.028.
Rush AJ, Sackeim HA, Marangell LB, George MS, Brannan SK, Davis SM, Lavori P, Howland R, Kling MA, Rittberg B, Carpenter L, Ninan P, Moreno F, Schwartz T, Conway C, Burke M, Barry JJ. Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol Psychiatry. 2005 Sep 1;58(5):355-63. doi: 10.1016/j.biopsych.2005.05.024.
Rush AJ, Marangell LB, Sackeim HA, George MS, Brannan SK, Davis SM, Howland R, Kling MA, Rittberg BR, Burke WJ, Rapaport MH, Zajecka J, Nierenberg AA, Husain MM, Ginsberg D, Cooke RG. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry. 2005 Sep 1;58(5):347-54. doi: 10.1016/j.biopsych.2005.05.025.
Cohen LJ, Allen JC Jr. Estimating the potential savings with vagus nerve stimulation for treatment-resistant depression: a payer perspective. Curr Med Res Opin. 2008 Aug;24(8):2203-17. doi: 10.1185/03007990802229050.
Nierenberg AA, Alpert JE, Gardner-Schuster EE, Seay S, Mischoulon D. Vagus nerve stimulation: 2-year outcomes for bipolar versus unipolar treatment-resistant depression. Biol Psychiatry. 2008 Sep 15;64(6):455-60. doi: 10.1016/j.biopsych.2008.04.036. Epub 2008 Jun 24.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D02
Identifier Type: -
Identifier Source: org_study_id